Bls Pharmaceuticals Limited (BLS.AX) stock: key figures, P/E, revenue and dividend

Health Care · Australia · ISIN AU0000477796

Price

1.00 AUD

Market cap

229.98 m AUD

P/E (2026)

14.94

P/S (2026)

3.10

Dividend yield

0.00 %

Net margin

20.76 %

Return on equity (ROE)

49.53 %

Return on assets (ROA)

29.56 %

Bls Pharmaceuticals Limited financials

Fiscal year	2026
Revenue	74.16 m AUD
Gross profit	41.56 m AUD
Operating income	15.80 m AUD
EBIT	15.62 m AUD
Net income	15.40 m AUD
Diluted EPS – continuing operations	0.07 AUD

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Bls Pharmaceuticals Limited

BLS Pharmaceuticals Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan. The company offers medical cannabis, MDMA, psilocybin, prescription medicines, probiotics, NADs, and consumer health products under the Dr Watson and PCC brands. It also provides pharmaceutical manufacturing, wholesale, distribution, import, export, and contract drug manufacturing services for investigational and psychotropic medicines. The company caters to licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors. The company was formerly known as Bioxyne Limited and changed its name to BLS Pharmaceuticals Limited in June 2026. BLS Pharmaceuticals Limited was incorporated in 1998 and is headquartered in Sydney, Australia.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.